Trial Profile
A Phase 1 Clinical Study of Intra-tumoural Injection or Intravenous Infusion of a Group B Oncolytic Adenovirus (ColoAd1) in Patients With Colon Cancer Who Are Candidates for Resection of Primary Tumour
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Jan 2023
Price :
$35
*
At a glance
- Drugs Enadenotucirev (Primary)
- Indications Colon cancer
- Focus Pharmacokinetics
- Acronyms MOA
- Sponsors Akamis Bio; PsiOxus Therapeutics
- 05 Jan 2023 According to an Akamis Bio media release, PsiOxus Therapeutics has changed its name to Akamis Bio.
- 08 Sep 2016 Status changed from active, no longer recruiting to completed.
- 31 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.